Last reviewed · How we verify
CD5024 0.3% cream
CD5024 0.3% cream is a topical calcineurin inhibitor that suppresses the immune system by inhibiting T-cell activation.
CD5024 0.3% cream is a topical calcineurin inhibitor that suppresses the immune system by inhibiting T-cell activation. Used for Atopic dermatitis.
At a glance
| Generic name | CD5024 0.3% cream |
|---|---|
| Also known as | Ivermectin |
| Sponsor | Galderma R&D |
| Drug class | calcineurin inhibitor |
| Target | calcineurin |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting calcineurin, CD5024 reduces the production of inflammatory cytokines and prevents the activation of T-cells, thereby reducing inflammation and immune responses. This mechanism is particularly useful in treating skin conditions characterized by excessive immune responses.
Approved indications
- Atopic dermatitis
Common side effects
- Skin burning sensation
- Redness
- Itching
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD5024 0.3% cream CI brief — competitive landscape report
- CD5024 0.3% cream updates RSS · CI watch RSS
- Galderma R&D portfolio CI